Location, Location, Location (7.26.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Location matters; Geo-rheumatology?
Read Article
Patients with Financial Limits Struggle with Medication Adherence
The National Health Interview Survey reveals that nearly 1 in 5 patients with rheumatologic disease in the U.S. face economic challenges, including food insecurity and CRM nonadherence.
https://t.co/DhiLDq3fjZ https://t.co/zqQRAJDrzc
Dr. John Cush @RheumNow( View Tweet )
Cross-sectional study of 154 adult DLE pts in the Philadelphia area assessed DLE Dz severity (by CLASI) & geoghraphic distribution to ID area deprivation (ADI). ADI > 5 (geospatial disadvantaged) was assoc w/ signif (4X) higher risk of mod-Severe Damage https://t.co/dgeGwzNTKm https://t.co/B3hmUE1G9U
Dr. John Cush @RheumNow( View Tweet )
Digital Self Screening for Arthritis Diagnosis
There are numerous impediments to diagnosis or referral; and a new study evaluates patient use of a mobile artificial intelligence (AI)–based symptom checker for diagnoses, but demonstrated only modest accuracy when applied to a cohort of patients with joint symptoms.
Read Article
Patients with Financial Limits Struggle with Medication Adherence
Analysis of the National Health Interview Survey shows that nearly 1 in 5 patients with rheumatologic disease in the United States struggled economically, suffering from food insecurity and cost related medication (CRM) nonadherence.
Read Article
Earlier RA Diagnosis Leads to Lower Costs of Care
A study from the Leiden Early Arthritis Clinic shows that is rheumatoid arthritis (RA) is diagnosed within 12 weeks after symptom onset, treatment costs were lower in both autoantibody-negative and autoantibody-positive RA.
The rheumatologist
Best Rheumatologists (7.19.2024)
This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.
Read Article
Geography of Arthritis-attributable Pain in the USA
The journal Pain has shown geographic differences in arthritis-attributable pain, arthritis-related outcomes mostly clustered in the Deep South and Appalachia, while severe arthritis pain is more prevalent in the Southwest, Pacific Northwest, Georgia, Florida, and Maine.
Read Article
Top 20 Best Rheumatology Hospitals - 2024
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 7th year in a row they have held this spot.
The top 5 rheumatology hospitals are largely the same as last year (with some minor shuffling) and includes
Read Article
ACR Comments on CMS Proposed 2025 Physician Payment Rule
ACR
The American College of Rheumatology (ACR) shared the following initial reaction to the proposed CY 2025 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program rule.
Read Article
Cost-Effectiveness of Biosimilars vs Leflunomide
An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar DMARDs were cost-effective compared with the conventional DMARD, leflunomide.
https://t.co/lWJB1VL1CL https://t.co/lzra8suVqs
Dr. John Cush @RheumNow( View Tweet )
Cost-Effectiveness of Biosimilars vs Leflunomide
An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) were cost-effective compared with the conventional DMARD, leflunomide. Does this suggest RA treatment guidelines need to be amended to allow
Read Article
ICYMI: 9 Facts about Leflunomide
Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. Here are some highpoints from this Medscape article and lecture.
Read Article
ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).
Read Article
ICYMI: BSR Guideline on Management of Sjogren’s Syndrome
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations. The British Society of Rheumatology has updated its 2017 guidelines, with wider evidence and
Read Article
Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
Read Article
Low Back Pain? Take a Walk!
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
Read Article
EULAR 2024 – Day 2 Report (A Difficult RA Day)
Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.
Read Article
EULAR 2024 - Day 1 Report
Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Read Article
Humira Clobbers Biosimilars in Battle for Part D Coverage
Medpage Today
Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.
Read Article
Is Cannabis Safe? (6.7.2024)
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
Read Article
2023 EULAR classification criteria for hand osteoarthritis
A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA).
The criteria require two mandatory criteria to be met:
must have
ACR Calls on CMS for Enhanced Transparency & Reporting
The American College of Rheumatology has submitted its response to the Centers for Medicare & Medicaid Services (CMS) request for information and feedback from stakeholders on how best to enhance Medicare Advantage data capabilities and increase public transparency.
Read Article
ACR’s Run at Goliath (PCPs) (5.31.2024)
Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?
Read Article
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO.
Recent Blogs
The advantage to patient care without the crutch of an EHR. What do you do?
Read Post
